Approaches to antithrombotic modification of vascular implants
- Authors: Sevostyanova VV1, Krivkina EO1, Antonova LV1
-
Affiliations:
- Research Institute for Complex Issues of Cardiovascular Diseases
- Issue: Vol 101, No 2 (2020)
- Pages: 232-242
- Section: Reviews
- URL: https://journal-vniispk.ru/kazanmedj/article/view/19226
- DOI: https://doi.org/10.17816/KMJ2020-232
- ID: 19226
Cite item
Abstract
Vascular implants in contact with blood must have high thrombotic resistance. However, in some cases, their implantation is associated with thrombosis and subsequent impaired patency of the blood vessel. Most often, this problem affects implants intended for reconstruction of small diameter vessels, which is associated with hemodynamic features in this part of the bloodstream. These include blood vessel prostheses, tissue-engineered vascular grafts, and endovascular stents. The features of the implant material are of great importance when choosing a method for its modification in order to improve biocompatibility and thromboresistance. The review analyzes current experience in using various methods of immobilizing drugs to the surface of vascular prostheses and endovascular stents made from stable and biodegradable polymers. The prospects of creating thromboresistant vascular grafts and stents by joint immobilization on the surface of the polymer material of drugs with antithrombogenic activity and biologically active molecules that regulate the reaction to a foreign body and implant remodeling were evaluated. Numerous studies in the review demonstrating a wide range of ways to modify blood vessel prostheses, tissue-engineered vascular grafts, and endovascular stents with antithrombotic drugs to increase their thrombosis resistance. The main approaches of antithrombotic modification include conjugation of drugs and biologically active molecules on the implant surface. At the same time, new technologies are aimed not only at inhibiting the process of thrombus formation, but also at reducing the intensity of the inflammation process and stimulating the reparation of vascular tissue.
Full Text
##article.viewOnOriginalSite##About the authors
V V Sevostyanova
Research Institute for Complex Issues of Cardiovascular Diseases
Email: leonora92@mail.ru
SPIN-code: 6536-6068
Russian Federation, Kemerovo, Russia
E O Krivkina
Research Institute for Complex Issues of Cardiovascular Diseases
Author for correspondence.
Email: leonora92@mail.ru
SPIN-code: 4560-0906
Russian Federation, Kemerovo, Russia
L V Antonova
Research Institute for Complex Issues of Cardiovascular Diseases
Email: leonora92@mail.ru
SPIN-code: 8634-3286
Scopus Author ID: 57189593385
ResearcherId: I-8624-2017
Russian Federation, Kemerovo, Russia
References
- Pashneh-Tala S., MacNeil S., Claeyssens F. The tissue-engineered vascular graft — past, present, and future. Tissue Eng. Part. B. Rev. 2016; 22 (1): 68–100. doi: 10.1089/ten.teb.2015.0100.
- Nakamura K., Keating J.H., Edelman E.R. Pathology of endovascular stents. Interv. Cardiol. Clin. 2016; 5 (3): 391–403. doi: 10.1016/j.iccl.2016.02.006.
- Hiob M.A., She S., Muiznieks L.D., Weiss A.S. Biomaterials and modifications in the development of small-diameter vascular grafts. ACS Biomater. Sci. Eng. 2017; 3 (5): 712–723. doi: 10.1021/acsbiomaterials.6b00220.
- Shoji T., Shinoka T. Tissue engineered vascular grafts for pediatric cardiac surgery. Transl. Pediatr. 2018; 7 (2): 188–195. doi: 10.21037/tp.2018.02.01.
- Radke D., Jia W., Sharma D. et al. Tissue engineering at the blood-contacting surface: A review of challenges and strategies in vascular graft development. Adv. Healthc. Mater. 2018; 7 (15): 1701461. doi: 10.1002/adhm.201701461.
- Ren X., Feng Y., Guo J. et al. Surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications. Chem. Soc. Rev. 2015; 44 (15): 5680–5742. doi: 10.1039/c4cs00483c.
- Maitz M.F., Martins M.C.L., Grabow N. et al. The blood compatibility challenge. Part 4: Surface modification for hemocompatible materials: Passive and active approaches to guide blood-material interactions. Acta. Biomater. 2019; 94: 33–43. doi: 10.1016/j.actbio.2019.06.019.
- Linhardt R.J. 2003 Claude S, Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J. Med. Chem. 2003; 19: 2551–2554. doi: 10.1021/jm030176m.
- Sasisekharan R., Venkataraman G. Heparin and heparan sulfate: biosynthesis, structure and function. Curr. Opin. Chem. Biol. 2000; 4 (6): 626–631. doi: 10.1016/s1367-5931(00)00145-9.
- Linhardt R.J., Murugesan S., Xie J. Immobilization of heparin: approaches and applications. Curr. Top. Med. Chem. 2008; 8 (2): 80–100. doi: 10.2174/156802608783378891.
- Sakiyama-Elbert S.E. Incorporation of heparin into biomaterials. Acta. Biomater. 2014; 10 (4): 1581–1587. doi: 10.1016/j.actbio.2013.08.045.
- Cannon C.P., Tracy R. Clotting for the clinician: an overview of thrombosis and antithrombotic therapy. J. Thromb. Thrombolysis. 1995; 2 (2): 95–106. doi: 10.1007/bf01064376.
- Wallén N.H., Ladjevardi M., Albert J., Bröijersén A. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. Thromb. Res. 1997; 87 (1): 151–157. doi: 10.1016/s0049-3848(97)00114-x.
- Aronson J.K. Side effects of drugs annual 26: A world-wide yearly survey of new data and trends in adverse drug reactions. Elsevier. 2003; 662 p.
- Hogg K., Weitz J.I. Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs. In: Goodman & Gilman’s: the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill. 2017; 849–876.
- Willard J.E., Lange R.A., Hillis L.D. The use of aspirin in ischemic heart disease. New Engl. J. Med. 1992; 327 (3): 175–181. doi: 10.1056/NEJM199207163270308.
- Topaz O. Cardiovascular thrombus: From pathology and clinical presentations to imaging, pharmacotherapy and interventions. Academic Press. 2018; 670 p.
- Grant S.M., Goa K.L. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs. 1992; 43 (6): 889–924. doi: 10.2165/00003495-199243060-00008.
- Shapiro J.R. Transient migratory osteoporosis in osteogenesis imperfecta. In: Osteogenesis Imperfecta. Academic Press. 2014; 359–370. doi: 10.1016/B978-0-12-397165-4.00039-3.
- Lin P.H., Bush R.L., Yao Q. et al. Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model. J. Surg. Res. 2004; 118 (1): 45–52. doi: 10.1016/j.jss.2003.12.026.
- Freeman J., Chen A., Weinberg R.J. et al. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded polytetrafluoroethylene propaten graft in a chronic canine femoral artery bypass model. Ann. Vasc. Surg. 2018; 49: 295–303. doi: 10.1016/j.avsg.2017.09.017.
- Al Meslmani B., Mahmoud G., Strehlow B. et al. Development of thrombus-resistant and cell compatible crimped polyethylene terephthalate cardiovascular grafts using surface co-immobilized heparin and collagen. Mater. Sci. Eng. C. Mater. Biol. Appl. 2014; 43: 538–546. doi: 10.1016/j.msec.2014.07.059.
- Zhu A.P., Ming Z., Jian S. Blood compatibility of chitosan/heparin complex surface modified ePTFE vascular graft. Applied Surf. Sci. 2005; 241 (3–4): 485–492. doi: 10.1016/j.apsusc.2004.07.055.
- Greco R.S., Kim H.C., Donetz A.P., Harvey R.A. Patency of a small vessel prosthesis bonded to tissue plasminogen activator and iloprost. Ann. Vasc. Surg. 1995; 9 (2): 140–145. doi: 10.1007/BF02139655.
- Heise M., Schmidmaier G., Husmann I. et al. PEG-hirudin/iloprost coating of small diameter ePTFE grafts effectively prevents pseudointima and intimal hyperplasia development. Eur. J. Vasc. Endovasc. Surg. 2006; 32 (4): 418–424. doi: 10.1016/j.ejvs.2006.03.002.
- Biran R., Pond D. Heparin coatings for improving blood compatibility of medical devices. Adv. Drug Deliv. Rev. 2017; 112: 12–23. doi: 10.1016/j.addr.2016.12.002.
- Duan H.Y., Ye L., Wu X. et al. The in vivo characterization of electrospun heparin-bonded polycaprolactone in small-diameter vascular reconstruction. Vascular. 2015; 23 (4): 358–365. doi: 10.1177/1708538114550737.
- Norouzi S.K., Shamloo A. Bilayered heparinized vascular graft fabricated by combining electrospinning and freeze drying methods. Mater. Sci. Eng. C. Mater. Biol. Appl. 2019; 94: 1067–1076. doi: 10.1016/j.msec.2018.10.016.
- Yao Y., Wang J., Cui Y. et al. Effect of sustained heparin release from PCL/chitosan hybrid small-diameter vascular grafts on anti-thrombogenic property and endothelialization. Acta. Biomater. 2014; 10 (6): 2739–2749. doi: 10.1016/j.actbio.2014.02.042.
- Aslani S., Kabiri M., Kehtari M., Hanaee-Ahvaz H. Vascular tissue engineering: Fabrication and characterization of acetylsalicylic acid-loaded electrospun scaffolds coated with amniotic membrane lysate. J. Cell Physiol. 2019; 234 (9): 16080–1609. doi: 10.1002/jcp.28266.
- Gao J., Jiang L., Liang Q. et al. The grafts modified by heparinization and catalytic nitric oxide generation used for vascular implantation in rats. Regen. Biomater. 2018; 5 (2): 105–114. doi: 10.1093/rb/rby003.
- Hu Y.T., Pan X.D., Zheng J. et al. In vitro and in vivo evaluation of a small-caliber coaxial electrospun vascular graft loaded with heparin and VEGF. Int. J. Surg. 2017; 44: 244–249. doi: 10.1016/j.ijsu.2017.06.077.
- Wang W., Liu D., Li D. et al. Nanofibrous vascular scaffold prepared from miscible polymer blend with heparin/stromal cell-derived factor-1 alpha for enhancing anticoagulation and endothelialization. Colloids Surf. B. Biointerfaces. 2019; 181: 963–972. doi: 10.1016/j.colsurfb.2019.06.065.
- Kuang H., Yang S., Wang Y. et al. Electrospun bilayer composite vascular graft with an inner layer modified by polyethylene glycol and haparin to regenerate the blood vessel. J. Biomed. Nanotechnol. 2019; 15 (1): 77–84. doi: 10.1166/jbn.2019.2666.
- Mori H., Gupta A., Torii S. et al. Clinical implications of blood-material interaction and drug eluting stent polymers in review. Expert Rev. Med. Devices. 2017; 14 (9): 707–716. doi: 10.1080/17434440.2017.1363646.
- Van der Giessen W.J., Lincoff A.M., Schwartz R.S. et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996; 94: 1690–1697. doi: 10.1161/01.cir.94.7.1690.
- Alt E., Haehnel I., Beilharz C. et al. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation. 2000; 101 (12): 1453–1458. doi: 10.1161/01.cir.101.12.1453.
- Lee C.H., Lin Y., Cjhang S. et al. Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery. Int. J. Nanomedicine. 2014; 9: 311–326. doi: 10.2147/IJN.S51258.
- Choi D.H., Kang S.N., Kim S.M. et al. Growth factors-loaded stents modified with hyaluronic acid and heparin for induction of rapid and tight re-endothelialization. Colloids Surf. B. Biointerfaces. 2016; 141: 602–610. doi: 10.1016/j.colsurfb.2016.01.028.
- Wang J., An Q., Li D. et al. Heparin and vascular endothelial growth factor loaded poly (L-lactide-co-caprolactone) nanofiber covered stent-graft for aneurysm treatment. J. Biomed. Nanotechnol. 2015; 11 (11): 1947–1960. doi: 10.1166/jbn.2015.2138.
- Liu P., Liu Y., Li P. et al. Rosuvastatin and heparin-loaded poly (l-lactide-co-caprolactone) nanofiber aneurysm stent promotes endothelialization via vascular endothelial growth factor type A modulation. ACS Appl. Mater. Interfaces. 2018; 10 (48): 41012–41018. doi: 10.1021/acsami.8b11714.
- Janjic M., Pappa F., Karagkiozaki V. et al. Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning. Int. J. Nanomedicine. 2017; 12: 6343–6355. doi: 10.2147/IJN.S138261.
- Liu Z., Li G., Zheng Z. et al. Silk fibroin-based woven endovascular prosthesis with heparin surface modification. J. Mater. Sci. Mater. Med. 2018; 29 (4): 46. doi: 10.1007/s10856-018-6055-3.
- Liu Z., Zheng Z., Chen K. et al. A heparin-functionalized woven stent graft for endovascular exclusion. Colloids Surf. B. Biointerfaces. 2019; 180: 118–126. doi: 10.1016/j.colsurfb.2019.04.027.
- Daenens K., Schepers S., Fourneau I. et al. Heparin-bonded ePTFE grafts compared with vein grafts in femoropopliteal and femorocrural bypasses: 1- and 2-year results. J. Vasc. Surg. 2009; 49 (5): 1210–1216. doi: 10.1016/j.jvs.2008.12.009.
- Samson R.H., Morales R., Showalter D.P. et al. Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison. J. Vasc. Surg. 2016; 64 (3): 638–647. doi: 10.1016/j.jvs.2016.03.414.
- Piffaretti G., Dorigo W., Castelli P. et al. Results from a multicenter registry of heparin-bonded expanded polytetrafluoroethylene graft for above-the-knee femoropopliteal bypass. J. Vasc. Surg. 2018; 67 (5): 1463–1471. doi: 10.1016/j.jvs.2017.09.017.
- Mehran R., Nikolsky E., Camenzind E. et al. An Internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation. Am. Heart J. 2005; 150 (6): 1171–1176. doi: 10.1016/j.ahj.2005.01.027.
Supplementary files
